12:00 AM
Sep 04, 2001
 |  BioCentury  |  Strategy

The City of Hope case

The ability of the City of Hope National Medical Center to win hundreds of millions of dollars in disputed royalties from Genentech Inc. probably will hinge on a trial jury's interpretation of competing clauses in the parties' contract that each side has invoked to make its case.

Jury selection started last week in the Los Angeles County Superior Court trial to hear the 1999 suit, which will decide whether the company owes additional royalties to City of Hope (Duarte, Calif.). The medical center is asking for compensatory damages that could approach $500 million in royalties from DNA (South San Francisco, Calif.).

Under the 1976 deal, the company agreed to fund recombinant DNA research at City of Hope in exchange for rights to patent resulting discoveries. DNA agreed to pay a 2% royalty...

Read the full 646 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >